Çeşitli Klinik Örneklerden Elde Edilen Stenotrophomonas maltophilia İzolatlarının Dağılımı ve Antibiyotik Duyarlılık Profili

Stenotrophomonas maltophilia is an opportunistic pathogen with limited therapeutic options that has been associated with various nosocomial or community-acquired infections, especially respiratory tract infections in newborns and elderly people. Antimicrobial resistance of the bacterium increases over the years and varies between geographical regions. The aim of this study was to retrospectively investigate the distribution and antibiotic susceptibility of S. maltophilia strains isolated in our hospital for three years. S. maltophilia strains isolated from various clinical samples between January 2022 and December 2024 were analyzed. Phoenix automated system (Becton Dickinson Diagnostic Instrument Systems, Sparks, USA) was used for bacterial identification and antimicrobial susceptibility testing. A total of 233 isolates were obtained during the study period. In the study, strains were most frequently isolated from respiratory tract samples (66.5%). 60.3% of the strains were isolated from patients treated in pediatric and adult intensive care units, while 11.1% were isolated from outpatients. 157 (67.4%) of the patients were between 65-95 years of age. Of the strains, 90.12% (210/233) were susceptible to trimethoprim/sulfamethoxazole (TMP/SXT) and 80.34% (184/229) to levofloxacin. In conclusion, our data suggest that elderly patients hospitalized in the intensive care unit should be carefully monitored for the development of S. maltophilia infection. While TMP-SXT was the most effective antimicrobial for S. maltophilia strains isolated in our hospital, the decrease in levofloxacin susceptibility over the years is remarkable. The susceptibility status for these two antimicrobials, which are important treatment options in S. maltophilia infections, should be followed up with new studies.